Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND MET investigators. Merker L, et al. Diabet Med. 2015 Dec;32(12):1555-67. doi: 10.1111/dme.12814. Epub 2015 Jul 14. Diabet Med. 2015. PMID: 26031566 Clinical Trial.
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators. Bode BW, et al. Among authors: merker l. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17. Diabet Med. 2013. PMID: 23710902 Free PMC article. Clinical Trial.
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG METSU Trial Investigators. Häring HU, et al. Among authors: merker l. Diabetes Care. 2013 Nov;36(11):3396-404. doi: 10.2337/dc12-2673. Epub 2013 Aug 20. Diabetes Care. 2013. PMID: 23963895 Free PMC article. Clinical Trial.
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ METSU investigators. Haering HU, et al. Among authors: merker l. Diabetes Res Clin Pract. 2015 Oct;110(1):82-90. doi: 10.1016/j.diabres.2015.05.044. Epub 2015 May 29. Diabetes Res Clin Pract. 2015. PMID: 26324220 Clinical Trial.
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ MONO investigators. Roden M, et al. Among authors: merker l. Cardiovasc Diabetol. 2015 Dec 23;14:154. doi: 10.1186/s12933-015-0314-0. Cardiovasc Diabetol. 2015. PMID: 26701110 Free PMC article. Clinical Trial.
[Nephropathy in diabetes].
Merker L. Merker L. MMW Fortschr Med. 2021 Apr;163(8):48-51. doi: 10.1007/s15006-021-9782-1. MMW Fortschr Med. 2021. PMID: 33904093 Review. German. No abstract available.
Nephropathy in Diabetes.
Merker L, Bautsch BW, Ebert T, Guthoff M, Isermann B. Merker L, et al. Exp Clin Endocrinol Diabetes. 2021 Aug;129(S 01):S60-S63. doi: 10.1055/a-1284-6211. Epub 2021 Jan 4. Exp Clin Endocrinol Diabetes. 2021. PMID: 33395705 No abstract available.
67 results